Cargando…
494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19...
Autores principales: | Rojanakit, Gun, Kiertiburanakul, Sasisopin, Boongird, Sarinya, Sutharattanapong, Napan, Yingchoncharoen, Teerapat, Sobhonslidsuk, Abhasnee, Bruminhent, Jackrapong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/ http://dx.doi.org/10.1093/ofid/ofad500.563 |
Ejemplares similares
-
Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022) -
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023) -
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023) -
Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)